Supplementary_Tables.docx (30.24 kB)
Download file

Supplementary Tables. Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations..docx

Download (30.24 kB)
dataset
posted on 30.11.2020, 00:26 by Karen L. Reckamp, Jasmine A. McQuerry, Isa Mambetsariev, Rebecca Pharaon, Susan E. Yost, Jeremy Fricke, Tamara Mirzapoiazova, Raju K. Pillai, Ziad Khan, Marwan Fakih, Yuan Yuan, Marianna Koczywas, Erminia Massarelli, Prakash Kulkarni, Sumanta K. Pal, Martin Sattler, Andrea Bild, Ravi Salgia

Supplementary Tables. Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations.

Background

The implication of MET alterations in solid tumors and the immune microenvironment remains elusive.

Materials & Methods

FFPE samples of 21 patients with solid tumors harboring MET alterations were used for IHC staining. Extracted RNA was analyzed with the NanoString nCounter human PanCancer Immune Profiling Panel.

Results

Patients were diagnosed with lung (N=10), breast (N=5), genitourinary (N=3), or colorectal cancer (N=3). Eleven had a MET missense mutation, 4 had an exon 14 splice site mutation, and 6 had MET amplification. CD6, CCL19, ATM, CD40LG, XCR1, MAGEA1, ATM and CCL19 genes were significantly differentially expressed in MET-altered cancers.

Conclusion

MET alterations may have a role in various solid tumors as potential therapeutic targets and combination therapy candidates with immune checkpoint inhibitors.

Funding

The work was supported by the National Cancer Institute of the National Institutes of Health under award numbers P30CA033572, U54CA209978, R01CA247471 and R01CA218545.

History